The drug atlas
Cardiovascular/Vitamin K antagonist

Warfarin

also: vitamin K antagonist · coumarin

Overview

Vitamin K antagonist still required where DOACs are contraindicated — mechanical valves and significant mitral stenosis. INR-monitored.

Mechanism

Inhibits vitamin-K epoxide reductase (VKORC1) → ↓regeneration of reduced vitamin K → ↓γ-carboxylation of clotting factors II, VII, IX, X and proteins C & S. Delayed onset (existing factors must degrade); initial transient procoagulant state (protein C falls first) → cover with heparin/LMWH when starting for VTE.

Indications

  • Mechanical heart valves (DOACs contraindicated)
  • Significant mitral stenosis with AF
  • VTE / AF where DOAC unsuitable
  • Antiphospholipid syndrome

Adverse effects

Bleedingserious

Reverse per severity: vitamin K ± PCC (Beriplex) for major bleeding; FFP if PCC unavailable.

Skin necrosisserious

Early, protein-C related — cover with heparin at initiation.

Teratogenicityserious

Warfarin embryopathy — switch to LMWH in pregnancy.

Purple toe syndromecommon

Cautions & contraindications

Pregnancy (esp. 1st trimester)pregnancy

Embryopathy; use LMWH.

Active bleeding / bleeding diathesisall
Recent haemorrhagic stroke / surgeryall

Interactions

  • CYP inducers (rifampicin, carbamazepine, St John's wort) → ↓INR
  • CYP inhibitors (clarithromycin, fluconazole, amiodarone, metronidazole) → ↑INR/bleeding
  • Cranberry/grapefruit juice
  • Alcohol (acute vs chronic differ)
  • Antiplatelets/NSAIDs ↑bleeding

Monitoring & kinetics

INR (target 2–3 most indications; 3–4 / 2.5–3.5 for mechanical valves),Reverse: vitamin K (slow), PCC (fast, for major bleeding)

Narrow therapeutic index; many food/drug interactions; effect delayed 48–72 h.

Choosing it

true

Source: BNF — Warfarin